(Reuters) – Solid Biosciences Inc said on Thursday the U.S. Food and Drug Administration (FDA) has lifted the clinical halt placed on a trial of its experimental gene therapy for a muscle-wasting disorder.
The trial was halted in November for a second time in less than two years after a seven-year-old-boy experienced serious complications.
Shares of the company were up nearly 60% in premarket trading after the news.
(Reporting By Mrinalika Roy in Bengaluru; Editing by Aditya Soni)
